Literature DB >> 20687497

Tuberous sclerosis complex and DNA repair.

Samy L Habib1.   

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder in humans characterized by the development of hamartomas in several organs, including renal angiomyolipomas, cardiac rhabdomyomas and subependymal giant cell astrocytomas. TSC causes disabling neurologic disorders, including epilepsy, mental retardation and autism. Brain lesions, including subependymal and subcortical hamartomas, have also been reported in TSC patients. TSC is associated with hamartomas and renal cell carcinoma (RCC) as well as sporadic tumors in TSC patient. Renal angiomyolipomas associated with TSC tend to be larger, bilateral, multifocal and present at a younger age compared with sporadic forms. Tuberous sclerosis complex of 2 genes, TSC2 encodes a protein called tuberin that normally exists in an active state and forms a heterodimeric complex with hamartin, the protein encoded by the TSC1. Deficiency ofTSC2 in Eker rat is associated with the development of tumors in several organs including kidney. The majority of renal cell tumors observed in the Eker rat originates from renal proximal tubules and are histologically similar to renal cell carcinoma in humans. On the other hand, mutations in DNA repair enzyme 8-oxoG-DNA glycosylase (OGG1) are associated with cancer. OGG1 gene is found somatically mutated in some cancer cells and is highly polymorphic among human cancers. Moreover, knockout mice in OGG1 developed spontaneously adenoma and carcinoma. We recently show that the constitutive expression of OGG1 in heterozygous (TSC2+/-) Eker rat and in angiomyolipomas kidney tissue from human is 2-3fold less than in kidney from wild-type rats and control human subjects. In addition, we show that loss of TSC2 in kidney tumor of Eker rat is associated with loss of OGG1 and accumulation significant levels of oxidative DNA damage 8-oxo-deoxyguanine suggesting that TSC2 and OGG1 play a major role in renal tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20687497     DOI: 10.1007/978-1-4419-6448-9_8

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

1.  Restoration of Normal Cerebral Oxygen Consumption with Rapamycin Treatment in a Rat Model of Autism-Tuberous Sclerosis.

Authors:  Oak Z Chi; Chang-Chih Wu; Xia Liu; Kang H Rah; Estela Jacinto; Harvey R Weiss
Journal:  Neuromolecular Med       Date:  2015-06-06       Impact factor: 3.843

2.  Time-matched analysis of DNA adduct formation and early gene expression as predictive tool for renal carcinogenesis in methylazoxymethanol acetate treated Eker rats.

Authors:  Valentina Klaus; Heinke Bastek; Katja Damme; Leonard B Collins; Roland Frötschl; Norbert Benda; Dominik Lutter; Heidrun Ellinger-Ziegelbauer; James A Swenberg; Daniel R Dietrich; Kerstin Stemmer
Journal:  Arch Toxicol       Date:  2017-03-27       Impact factor: 5.153

3.  Long-term High Fat Ketogenic Diet Promotes Renal Tumor Growth in a Rat Model of Tuberous Sclerosis.

Authors:  Arkadiusz D Liśkiewicz; Daniela Kasprowska; Anna Wojakowska; Krzysztof Polański; Joanna Lewin-Kowalik; Katarzyna Kotulska; Halina Jędrzejowska-Szypułka
Journal:  Sci Rep       Date:  2016-02-19       Impact factor: 4.379

4.  Enhanced Susceptibility of Ogg1 Mutant Mice to Multiorgan Carcinogenesis.

Authors:  Anna Kakehashi; Naomi Ishii; Takahiro Okuno; Masaki Fujioka; Min Gi; Hideki Wanibuchi
Journal:  Int J Mol Sci       Date:  2017-08-18       Impact factor: 5.923

5.  Familial genetic tuberous sclerosis complex associated with bilateral giant renal angiomyolipoma: A case report.

Authors:  Lina Wang; Dawei Ni; Lin Zhong; Jianbo Wang
Journal:  Oncol Lett       Date:  2017-10-10       Impact factor: 2.967

6.  A new drug combination significantly reduces kidney tumor progression in kidney mouse model.

Authors:  Sitai Liang; Tiffanie Cuellar; Maciej Nowacki; Bijaya K Nayak; Lily Dong; Boajie Li; Kumar Sharma; Samy L Habib
Journal:  Oncotarget       Date:  2018-08-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.